3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
69
Triple Negative Breast Neoplasms
32
Ovarian Neoplasms
21
Neoplasm Metastasis
10
Prostatic Neoplasms
8
Pancreatic Neoplasms
7
Fanconi Anemia, Complementation Group D1
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Advanced Breast Cancer
4
Recurrence
3
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Inflammatory Breast Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Sarcoma
1
Radiation Injuries
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian
1
Interventions
Radiotherapy
4
Radiotherapy, Intensity-Modulated
2
Low-Level Light Therapy
2
Chemotherapy, Adjuvant
2
olaparib
1
Sodium Chloride
1
Respiratory Physiological Phenomena
1
Radiotherapy, Conformal
1
Radiation Dose Hypofractionation
1
Proton Therapy
1
Poly A
1
Oxygen
1
Mometasone Furoate
1
Mass Screening
1
Lymph Node Excision
1
Lovastatin
1
Hyperbaric Oxygenation
1
Gene Expression Profiling
1
G(M1) Ganglioside
1
Flow Cytometry
1
Enzyme-Linked Immunosorbent Assay
1
Diagnosis
1
Centella asiatica extract
1
Blood Specimen Collection
1
Adenosine Diphosphate Ribose
1
Adenosine Diphosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Radiation Injuries
×
olaparib
×
Breast
×
Clear all
NCT03109080
2025-11-24
RadioPARP
Institut Curie
Phase 1
Completed
24 enrolled